Skip to main content
    W

    Werewolf Therapeutics Inc (HOWL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.05
    +0.06 (+5.97%)

    Market Cap: $47.64M

    Last updated: Nov 17, 2026 at 4:21 PM ET

    Werewolf Therapeutics Inc (HOWL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Werewolf Therapeutics (HOWL) has a market cap of $47.64M and an enterprise value of $5.77M. It kept -133.90% of revenue as net income over the last 12 months. It holds $41.87M more cash than debt, 87.89% of its market cap.

    Total Valuation

    Enterprise value is 87.89% below the market cap, as cash exceeds debt.

    Market Cap$47.64M
    Enterprise Value$5.77M
    Latest price (Nov 17, 2026)$1.05

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 5.45% a year over 2 years.

    Shares Outstanding48.60M
    Shares Change (YoY)+6.10%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+5.45%

    Valuation Ratios

    Sales and book value multiples are 2.4x and 7.5x. Its year-end P/S ranged from 3.7x to 34.4x from 2022 to 2024.

    P/S Ratio2.4x
    P/B Ratio7.5x

    Valuation history and multiples

    Price Statistics

    The stock is up 14.35% over 52 weeks and trades 6.06% above its 50-day average.

    Beta (1Y)1.56
    52-Week Change+14.35%
    1-Month Change+0.96%
    3-Month Change+156.54%
    6-Month Change+145.10%
    5-Year Change-93.71%
    Total Return (1Y)+14.35%
    Total Return (3Y CAGR)-23.00%
    Total Return (5Y CAGR)-42.27%
    Max Drawdown (1Y)-72.00%
    Max Drawdown (3Y)-96.11%
    Sharpe Ratio (1Y)0.11
    Correlation with SPY (1Y)0.17
    50-Day Average$0.99
    200-Day Average$0.70
    52-Week Range$0.27 to $1.20
    RSI (14 Days)57.0
    Average Volume (20 Days)343.79K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.19x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.19x
    Quick Ratio1.19x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -416.04% over the last 12 months, against a 5-year average of -90.31%.

    Return on Equity (ROE)-416.04%
    Return on Assets (ROA)-65.77%
    Return on Capital Employed (ROCE)-340.45%
    ROE (5Y Average)-90.31%
    ROA (5Y Average)-45.21%
    ROIC (5Y Average)-50.58%
    Asset Turnover0.34x

    Scores

    HOWL has an Altman Z-Score of -16.46, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-16.46
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $21.00M over the last 12 months.

    Revenue$21.00M
    Gross Profit$20.60M
    Operating Income-$25.59M
    Pretax Income-$28.12M
    Net Income-$28.12M
    EBITDA-$18.28M
    EBIT-$23.01M
    Reported EPS (TTM)-$0.57

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 15.81% of the $42.75M in total assets.

    Cash and Equivalents$41.87M
    Total Debt$0
    Net Cash$41.87M
    Net Cash Per Share$0.86
    Working Capital$6.76M
    Shareholder Equity$6.76M
    Book Value Per Share$0.14
    Total Assets$42.75M
    Total Liabilities$35.99M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$23.96M
    FCF Per Share-$0.49
    Depreciation and Amortization$4.73M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -121.83%.

    Gross Margin98.10%
    Operating Margin-121.83%
    Pretax Margin-133.90%
    Net Margin-133.90%
    EBITDA Margin-87.05%
    EBIT Margin-109.58%

    Growth

    Book Value Per Share Growth (2Y CAGR)-58.29%
    Tangible Book Per Share Growth (2Y CAGR)-58.29%

    Revenue and profit by year

    Dividends and Yields

    HOWL does not pay a dividend.

    Buyback Yield-4.64%
    Shareholder Yield-4.64%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HOWL

    What is HOWL's market cap?

    Werewolf Therapeutics has a market cap of $47.64M. Its enterprise value, which adds debt and subtracts cash, is $5.77M.

    How many shares of HOWL are outstanding?

    Werewolf Therapeutics has 48.60M shares outstanding. The count is up 6.10% from a year earlier.

    Does HOWL pay a dividend?

    No. Werewolf Therapeutics does not pay a dividend.

    How much debt does HOWL have?

    Werewolf Therapeutics has $0 of total debt and $41.87M of cash and equivalents, a net cash position of $41.87M.